186 related articles for article (PubMed ID: 30513220)
21. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
25. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.
Sidana S; Milani P; Binder M; Basset M; Tandon N; Foli A; Dispenzieri A; Gertz MA; Hayman SR; Buadi FK; Lacy MQ; Kapoor P; Leung N; Rajkumar SV; Merlini G; Palladini G; Kumar SK
Blood Cancer J; 2020 Apr; 10(4):41. PubMed ID: 32286270
[TBL] [Abstract][Full Text] [Related]
26. Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
Sachchithanantham S; Berlanga O; Alvi A; Mahmood SA; Lachmann HJ; Gillmore JD; Hawkins PN; Harding S; Wechalekar AD
Br J Haematol; 2017 Nov; 179(4):575-585. PubMed ID: 28990174
[TBL] [Abstract][Full Text] [Related]
27. AL amyloidosis: The effect of fluorescent in situ hybridization abnormalities on organ involvement and survival.
Ozga M; Zhao Q; Benson D; Elder P; Williams N; Bumma N; Rosko A; Chaudhry M; Khan A; Devarakonda S; Kahwash R; Vallakati A; Campbell C; Parikh SV; Almaani S; Prosek J; Bittengle J; Pfund K; LoRusso S; Freimer M; Redder E; Efebera Y; Sharma N
Cancer Med; 2021 Feb; 10(3):965-973. PubMed ID: 33347707
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation.
Cornell RF; Zhong X; Arce-Lara C; Atallah E; Blust L; Drobyski WR; Fenske TS; Pasquini MC; Rizzo JD; Saber W; Hari PN
Bone Marrow Transplant; 2015 Jul; 50(7):914-7. PubMed ID: 25915809
[TBL] [Abstract][Full Text] [Related]
29. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E; Gavriatopoulou M; Roussou M; Fotiou D; Ziogas DC; Migkou M; Eleutherakis-Papaiakovou E; Panagiotidis I; Kanellias N; Psimenou E; Papadopoulou E; Pamboucas C; Manios E; Gakiopoulou H; Ntalianis A; Tasidou A; Giannouli S; Terpos E; Dimopoulos MA
Blood Cancer J; 2017 Jun; 7(6):e570. PubMed ID: 28622303
[TBL] [Abstract][Full Text] [Related]
30. Management of AL amyloidosis in 2020.
Palladini G; Milani P; Merlini G
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
[TBL] [Abstract][Full Text] [Related]
31. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of interventricular septal thickness in patients with AL amyloidosis.
Cho H; Kim SJ; Shim CY; Hong GR; Ha JW; Kim YR; Yang WI; Chung H; Jang JE; Cheong JW; Min YH; Kim JS
Leuk Res; 2017 Sep; 60():36-43. PubMed ID: 28648672
[TBL] [Abstract][Full Text] [Related]
33. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
34. Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.
Ravichandran S; Cohen OC; Law S; Sachchithanantham S; Mahmood S; Foard D; Fontana M; Martinez-Naharro A; Whelan C; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
Br J Haematol; 2021 Aug; 194(3):587-597. PubMed ID: 34189728
[TBL] [Abstract][Full Text] [Related]
35. Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
Manwani R; Mahmood S; Sachchithanantham S; Lachmann HJ; Gillmore JD; Yong K; Rabin N; Popat R; Kyriakou C; Worthington S; Sharpley F; Smith M; Shah R; Cheesman S; Hawkins PN; Wechalekar AD
Br J Haematol; 2019 Dec; 187(5):638-641. PubMed ID: 31388995
[TBL] [Abstract][Full Text] [Related]
36. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
Sidana S; Narkhede M; Elson P; Hastings D; Faiman B; Valent J; Samaras C; Hamilton K; Liu HK; Smith MR; Reu FJ
PLoS One; 2017; 12(3):e0172996. PubMed ID: 28278302
[TBL] [Abstract][Full Text] [Related]
37. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
Gustine JN; Staron A; Mendelson L; Joshi T; Gopal DM; Siddiqi OK; Ruberg FL; Sanchorawala V
Blood Adv; 2023 Oct; 7(20):6080-6091. PubMed ID: 37581513
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
Huang X; Wang Q; Chen W; Ren G; Liu Z
Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
Lamm W; Willenbacher W; Lang A; Zojer N; Müldür E; Ludwig H; Schauer-Stalzer B; Zielinski CC; Drach J
Ann Hematol; 2011 Feb; 90(2):201-6. PubMed ID: 20821326
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of left atrial function in systemic light-chain amyloidosis: a cardiac magnetic resonance study.
Mohty D; Boulogne C; Magne J; Varroud-Vial N; Martin S; Ettaif H; Fadel BM; Bridoux F; Aboyans V; Damy T; Jaccard A
Eur Heart J Cardiovasc Imaging; 2016 Sep; 17(9):961-9. PubMed ID: 27194782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
